For research use only. Not for use in humans.

Seribantumab (Anti-ERBB3 / HER3)

Synonyms: ErbB-3, HER3

Seribantumab (Anti-ERBB3 / HER3) is a fully human IgG2 monoclonal antibody that targets HER3. It inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models. MW : 143.14 KD.

Seribantumab (Anti-ERBB3 / HER3)

Quality Control

Batch: A266001 Purity: 99% Protein concentration: 14.36mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation HER2 Others
Canertinib (CI-1033) 51 EGFR
CP-724714 109
Sapitinib (AZD8931) 50 ErbB3,EGFR
CUDC-101 23 EGFR,HDAC,HDAC1
Mubritinib (TAK 165) 41
AEE788 (NVP-AEE788) 16 EGFR,c-Abl,FLT1
AC480 (BMS-599626) 12 HER1,HER4
TAK-285 5 EGFR/HER1,HER4,MEK1
Tyrphostin AG 879 3 Trk
Tuxobertinib (BDTX-189) 3 EGFR,RIPK2,BLK
Epertinib hydrochloride 1 EGFR,HER4
TAS0728 1
Tyrphostin AG-528 0 EGFR
SU5204 1 VEGFR-2
Pyrotinib dimaleate 6 EGFR
Poziotinib (NOV120101, HM781-36B) 37 HER1,HER4
HER2-Inhibitor-1 1
Zongertinib (BI 1810631) 1 EGFR-Ex20ins
Nordihydroguaiaretic acid (NDGA) 2 p300,IGF-1R,lipoxygenase
EGCG ((-)-Epigallocatechin Gallate) 42 FASN,EGFR,DNMT
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Seribantumab (Anti-ERBB3 / HER3) is a fully human IgG2 monoclonal antibody that targets HER3. It inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models. MW : 143.14 KD.
References

Product Details

CAS No. 1334296-12-6
Molecular Weight 143.14
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06731907 RECRUITING Drug: Carboplatin|Drug: Paclitaxel|Drug: Nab-paclitaxel|Drug Non-small Cell Lung Cancer Merck Sharp & Dohme LLC 2025-03-30 PHASE2
NCT04165070 RECRUITING Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed Carcinoma, Non-Small-Cell Lung Merck Sharp & Dohme LLC 2019-12-19 PHASE1; PHASE2
NCT05919537 ACTIVE_NOT_RECRUITING Drug: HMBD-001|Drug: Docetaxel|Drug: Nab-paclitaxel|Drug: Ge Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Metastatic Solid Tumor Hummingbird Bioscience 2023-09-06 PHASE1
NCT07701941 NOT_YET_RECRUITING Drug: Patritumab deruxtecan|Drug: Trastuzumab deruxtecan Hormone Receptor Positive; HER2-low or HER2-ultralow; Unresectable or Metastatic Breast Cancer Daiichi Sankyo 2026-08-03 PHASE1; PHASE2
NCT05142189 RECRUITING Drug: Docetaxel|Drug: Carboplatin|Drug: Paclitaxel Non-Small Cell Lung Cancer BioNTech SE 2022-06-17 PHASE1
NCT07193394 RECRUITING Drug: Tucatinib (ONT-380)|Drug: Trastuzumab (Herceptin) Metastatic Breast Cancer ( HER2 Negative); Unresectable Breast Cancer Institut Curie 2026-01-31 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-18)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.